Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Published

Journal Article

BACKGROUND: Atrial fibrillation (AFib) is a common comorbidity in HF and affects patients' outcome. We sought to assess the effects of serelaxin in patients with and without AFib. METHODS: In a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram. RESULTS: AFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (-63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518). CONCLUSIONS: Serelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

Full Text

Duke Authors

Cited Authors

  • Filippatos, G; Farmakis, D; Metra, M; Cotter, G; Davison, BA; Felker, GM; Greenberg, BH; Hua, TA; Pang, PS; Ponikowski, P; Qian, M; Severin, TA; Voors, AA; Teerlink, JR

Published Date

  • June 2017

Published In

Volume / Issue

  • 106 / 6

Start / End Page

  • 444 - 456

PubMed ID

  • 28150186

Pubmed Central ID

  • 28150186

Electronic International Standard Serial Number (EISSN)

  • 1861-0692

Digital Object Identifier (DOI)

  • 10.1007/s00392-016-1074-x

Language

  • eng

Conference Location

  • Germany